Compare Stocks: BTAI, INAB, MDXH, and CMMB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BTAI BioXcel Therapeutics	$0.07 +0.3%	$0.43	$0.07 ▼ $4.29	$2.32M	0.19	17.36 million shs	42.29 million shs
CMMB Chemomab Therapeutics	$1.18 +1.7%	$1.88	$0.92 ▼ $3.07	$7.97M	0.74	37,680 shs	76,439 shs
INAB IN8bio	$0.91 +1.0%	$1.15	$0.87 ▼ $2.73	$10.06M	0.3	43,283 shs	9,321 shs
MDXH MDxHealth	$0.16 -3.9%	$0.54	$0.15 ▼ $4.93	$9.50M	1.68	1.81 million shs	786,236 shs

7 Energy Stocks to Buy and Hold Forever

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BTAI BioXcel Therapeutics	0.00%	0.00%	0.00%	-91.39%	-96.39%
CMMB Chemomab Therapeutics	+1.72%	+18.00%	-17.48%	-29.76%	-61.44%
INAB IN8bio	+0.97%	-5.75%	-35.00%	-5.22%	-53.33%
MDXH MDxHealth	-3.86%	-19.36%	-72.50%	-64.48%	-96.81%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BTAI BioXcel Therapeutics	$0.07 +0.3%	$0.43	$0.07 ▼ $4.29	$2.32M	0.19	17.36 million shs	42.29 million shs
CMMB Chemomab Therapeutics	$1.18 +1.7%	$1.88	$0.92 ▼ $3.07	$7.97M	0.74	37,680 shs	76,439 shs
INAB IN8bio	$0.91 +1.0%	$1.15	$0.87 ▼ $2.73	$10.06M	0.3	43,283 shs	9,321 shs
MDXH MDxHealth	$0.16 -3.9%	$0.54	$0.15 ▼ $4.93	$9.50M	1.68	1.81 million shs	786,236 shs

7 Energy Stocks to Buy and Hold Forever

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BTAI BioXcel Therapeutics	0.00%	0.00%	0.00%	-91.39%	-96.39%
CMMB Chemomab Therapeutics	+1.72%	+18.00%	-17.48%	-29.76%	-61.44%
INAB IN8bio	+0.97%	-5.75%	-35.00%	-5.22%	-53.33%
MDXH MDxHealth	-3.86%	-19.36%	-72.50%	-64.48%	-96.81%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BTAI BioXcel Therapeutics	2.25	Hold	$11.00	14,744.80% Upside
CMMB Chemomab Therapeutics	1.50	Reduce	N/A	N/A
INAB IN8bio	2.00	Hold	N/A	N/A
MDXH MDxHealth	2.00	Hold	$1.33	749.26% Upside

Current Analyst Ratings Breakdown

Latest BTAI, INAB, MDXH, and CMMB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/19/2026	MDXH MDxHealth	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Buy ➝ Neutral
10/16/2026	MDXH MDxHealth	Lake Street Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Buy ➝ Hold	$0.50
10/16/2026	MDXH MDxHealth	Craig Hallum Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Buy ➝ Hold
10/15/2026	INAB IN8bio	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
9/16/2026	CMMB Chemomab Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
9/8/2026	MDXH MDxHealth	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
9/2/2026	CMMB Chemomab Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
8/21/2026	MDXH MDxHealth	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$4.00 ➝ $2.00
8/19/2026	CMMB Chemomab Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
8/14/2026	MDXH MDxHealth	Lake Street Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target	Buy	$5.00 ➝ $3.00
8/5/2026	CMMB Chemomab Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)

(Data available from 11/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BTAI BioXcel Therapeutics	$640K	3.63	N/A	N/A	($4.37) per share	-0.02
CMMB Chemomab Therapeutics	N/A	N/A	N/A	N/A	$2.00 per share	N/A
INAB IN8bio	N/A	N/A	N/A	N/A	$2.82 per share	N/A
MDXH MDxHealth	$107.88M	0.07	N/A	N/A	($0.24) per share	-0.65

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BTAI BioXcel Therapeutics	-$69.90M	-$3.79	N/A	N/A	N/A	-9,549.87%	N/A	-185.82%	11/11/2026 (Estimated)
CMMB Chemomab Therapeutics	-$8.99M	-$2.13	N/A	N/A	N/A	N/A	-92.14%	-82.05%	11/6/2026 (Estimated)
INAB IN8bio	-$19.44M	-$1.62	N/A	N/A	N/A	N/A	-91.18%	-76.93%	11/5/2026 (Estimated)
MDXH MDxHealth	-$33.52M	-$0.72	N/A	N/A	N/A	-33.46%	N/A	-24.25%	N/A

Latest BTAI, INAB, MDXH, and CMMB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/6/2026	Q3 2026	CMMB Chemomab Therapeutics	-$0.01	N/A	N/A	N/A	N/A	N/A
11/5/2026	Q3 2026	INAB IN8bio	-$0.3367	N/A	N/A	N/A	N/A	N/A
8/20/2026	Q2 2026	CMMB Chemomab Therapeutics	-$0.15	-$0.27	-$0.12	-$0.24	N/A	N/A
8/14/2026	Q2 2026	MDXH MDxHealth	-$0.1934	-$0.18	+$0.0134	-$0.22	$26.14 million	$27.21 million
8/13/2026	Q2 2026	BTAI BioXcel Therapeutics	-$0.44	-$0.49	-$0.05	-$0.49	$0.49 million	$0.18 million
8/6/2026	Q2 2026	INAB IN8bio	-$0.3437	-$0.25	+$0.0937	-$0.25	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BTAI BioXcel Therapeutics	N/A	N/A	N/A	N/A	N/A
CMMB Chemomab Therapeutics	N/A	N/A	N/A	N/A	N/A
INAB IN8bio	N/A	N/A	N/A	N/A	N/A
MDXH MDxHealth	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BTAI BioXcel Therapeutics	N/A	0.21	0.21
CMMB Chemomab Therapeutics	N/A	6.41	6.41
INAB IN8bio	N/A	8.21	8.21
MDXH MDxHealth	N/A	1.15	0.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BTAI BioXcel Therapeutics	30.68%
CMMB Chemomab Therapeutics	46.05%
INAB IN8bio	92.05%
MDXH MDxHealth	N/A

Insider Ownership

Company	Insider Ownership
BTAI BioXcel Therapeutics	3.70%
CMMB Chemomab Therapeutics	11.91%
INAB IN8bio	14.50%
MDXH MDxHealth	1.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BTAI BioXcel Therapeutics	90	31.31 million	30.15 million	Optionable
CMMB Chemomab Therapeutics	12	7.25 million	6.38 million	Not Optionable
INAB IN8bio	18	9.86 million	8.43 million	Not Optionable
MDXH MDxHealth	364	49.50 million	48.66 million	Not Optionable

BTAI, INAB, MDXH, and CMMB Headlines

Recent News About These Companies

Mdxhealth to Release Third Quarter 2026 Financial Results on November 12

October 29, 2026 | globenewswire.com

Evaxion A/S (NASDAQ:EVAX) versus MDxHealth (NASDAQ:MDXH) Critical Contrast

October 29, 2026 | americanbankingnews.com

MDxHealth consensus price target cut by 19.64% to $1.15

October 23, 2026 | msn.com

BTIG Downgrades MDxHealth to Neutral From Buy

October 19, 2026 | marketscreener.comM

MdxHealth suspends 2026 guidance as Q3 revenue misses targets

October 16, 2026 | streetinsider.com

MDxHealth SA Provides Preliminary Unaudited Revenue Guidance for the Third Quarter Ended September 30, 2026

October 16, 2026 | marketscreener.comM

MDxHealth SA Provides Preliminary Unaudited Revenue Guidance for the Third Quarter Ended September 30, 2026

October 16, 2026 | marketscreener.comM

MDxHealth SA Suspends Revenue Guidance for the Full Year of 2026

October 15, 2026 | marketscreener.comM

MDxHealth Suspends 2026 Revenue Guidance After Preliminary Q3 Revenue

October 15, 2026 | marketscreener.comM

MDxHealth Pulls Outlook as 3Q Sales Underwhelm

October 15, 2026 | marketwatch.com

MDxHealth Announces Preliminary Third Quarter 2026 Revenue and Suspends Full-Year 2026 Revenue Guidance

October 15, 2026 | globenewswire.com

MDxHealth stock heads into November results with a USD 30.8 million cap

October 7, 2026 | ad-hoc-news.deA

MDxHealth consensus price target lowered by 22.22% to $1.43

October 2, 2026 | msn.com

MDxHealth stock holds steady as investors digest latest quarterly figures

September 19, 2026 | ad-hoc-news.deA

MDxHealth Files 2026 Interim Report as Losses Deepen but Fresh Capital Extends Runway

September 3, 2026 | tipranks.com

MDxHealth (MDXH) Q2 2026 Earnings Call Transcript

August 21, 2026 | fool.com

3 Top Penny Stocks to Watch Today, 8/18/26

August 18, 2026 | tipranks.com

MDxHealth Soars to Record-Breaking Quarter with 14% Sequential Revenue Increase

August 17, 2026 | news.themarketisopen.comN

MDxHealth S.A. Q2 2026 Earnings Call Summary

August 15, 2026 | finance.yahoo.com

MDxHealth says well-positioned to 'return to positive EBITDA'

August 14, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BTAI, INAB, MDXH, and CMMB Company Descriptions

BioXcel Therapeutics NASDAQ:BTAI

BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.

Chemomab Therapeutics NASDAQ:CMMB

$1.18 +0.02 (+1.72%)

Closing price 11/2/2026 04:00 PM Eastern

Extended Trading

$1.18 +0.01 (+0.42%)

As of 11/2/2026 07:45 PM Eastern

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

IN8bio NASDAQ:INAB

$0.91 +0.01 (+0.97%)

Closing price 11/2/2026 04:00 PM Eastern

Extended Trading

$0.98 +0.07 (+7.36%)

As of 11/2/2026 07:08 PM Eastern

IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell therapeutic and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company's lead programs consist of INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation. The Company is also developing INB-200/400, an autologous genetically modified γδ T cell candidate for newly diagnosed Glioblastoma (GBM). The preclinical pipeline includes a novel γδ T cell engager platform, INB-600, which activates and expands γδ T cells in vivo for deep target cell depletion and is being developed for oncology and autoimmune indications.

MDxHealth NASDAQ:MDXH

$0.16 -0.01 (-3.86%)

Closing price 11/2/2026 04:00 PM Eastern

Extended Trading

$0.17 +0.01 (+5.73%)

As of 11/2/2026 07:47 PM Eastern

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BTAI, INAB, MDXH, and CMMB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BTAI, INAB, MDXH, and CMMB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BTAI, INAB, MDXH, and CMMB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BTAI, INAB, MDXH, and CMMB Company Descriptions

BioXcel Therapeutics NASDAQ:BTAI

Chemomab Therapeutics NASDAQ:CMMB

IN8bio NASDAQ:INAB

MDxHealth NASDAQ:MDXH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BTAI, INAB, MDXH, and CMMB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BTAI, INAB, MDXH, and CMMB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BTAI, INAB, MDXH, and CMMB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BTAI, INAB, MDXH, and CMMB Company Descriptions

BioXcel Therapeutics NASDAQ:BTAI

Chemomab Therapeutics NASDAQ:CMMB

IN8bio NASDAQ:INAB

MDxHealth NASDAQ:MDXH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools